We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
126
Voyager Therapeutics
VYGR
$183M
$327K 0.05%
55,857
– –
RAPT
127
DELISTED
RAPT Therapeutics
RAPT
$311K 0.04%
19,328
– –
ANEB
128
DELISTED
Anebulo Pharmaceuticals
ANEB
$305K 0.04%
157,862
– –
APGE icon
129
CALL
Apogee Therapeutics
APGE
$10.1B
$294K 0.04%
+5,000
New +$240K
TARA icon
130
Protara Therapeutics
TARA
$220M
$285K 0.04%
155,712
-25,000
-14% -$51.4K
LYRA
131
DELISTED
LYRA THERAPEUTICS INC
LYRA
$272K 0.04%
21,137
– –
AEON icon
132
AEON Biopharma
AEON
$12.9M
$271K 0.04%
3,583
– –
FULC icon
133
Fulcrum Therapeutics
FULC
$273M
$268K 0.04%
+75,000
New +$556K
MGNX icon
134
MacroGenics
MGNX
$235M
$263K 0.04%
80,079
-120,000
-60% -$467K
HOOK
135
DELISTED
HOOKIPA Pharma
HOOK
$228K 0.03%
+53,076
New +$280K
PRTA icon
136
CALL
Prothena Corp
PRTA
$425M
$197K 0.03%
+11,800
New +$254K
PRTA icon
137
PUT
Prothena Corp
PRTA
$425M
$197K 0.03%
+11,800
New +$254K
NUVB icon
138
Nuvation Bio
NUVB
$2.2B
$191K 0.03%
83,282
-275,000
-77% -$839K
TPST icon
139
Tempest Therapeutics
TPST
$13.7M
$148K 0.02%
8,123
– –
RLMD icon
140
Relmada Therapeutics
RLMD
$557M
$131K 0.02%
40,369
– –
STOK icon
141
Stoke Therapeutics
STOK
$1.8B
$83.8K 0.01%
6,816
– –
FULC icon
142
PUT
Fulcrum Therapeutics
FULC
$273M
$81.4K 0.01%
+22,800
New +$169K
SYBX
143
DELISTED
Synlogic
SYBX
$30.5K ﹤0.01%
20,448
– –
CTMX icon
144
CytomX Therapeutics
CTMX
$675M
$10.5K ﹤0.01%
8,924
– –
FDMT icon
145
4D Molecular Therapeutics
FDMT
$532M
$421 ﹤0.01%
+39
New +$647
ABEO icon
146
CALL
Abeona Therapeutics
ABEO
$366M
– –
-171
Closed -$72.5K
ALNY icon
147
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-1,500
Closed -$36.5M
ALNY icon
148
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-1,500
Closed -$36.5M
ANNX icon
149
Annexon
ANNX
$835M
– –
-380,000
Closed -$1.86M
ANVS icon
150
CALL
Annovis Bio
ANVS
$74.4M
– –
-517
Closed -$298K
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.